news

Krishnamurthy & Co (K Law) and Shardul Amarchand Mangaldas have advised biopharmaceutical company Biocon on the $730 million sale of a 15 percent stake in subsidiary Biocon Biologics to Serum Institute of India (SII), which was represented by Veritas Legal.

The deal will grant SII access to 100 million doses of vaccines annually for 15 years.

Biocon Biologics develops affordable biosimilars. SII, the maker of AstraZeneca's COVID-19 shot, which is branded as Covishield in India, is the world's largest vaccine maker.

The deal with SII values Biocon Biologics at about $4.9 billion and will solely focus on COVID-19 vaccines in the initial years, reported Reuters.

Partner Naina Krishna Murthy led the K Law team.

Meanwhile, the SAM team was led by partners Iqbal Khan, Ambarish, Shahana Chatterji, Mukul Baveja, Meghna Rajadhyaksha, Ashoo Gupta, Aparna Mehra and Gauri Chhabra.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

NO&T, STB, AMT, Davis Polk advise on Japan's biggest IPO in 6 years

by Asian Legal Business《亚洲法律杂志》 |

Nagashima Ohno & Tsunematsu and Simpson Thacher & Bartlett have advised Tokyo Metro on its 348.6 billion yen ($2.3 billion) initial public offering, Japan's largest in six years.

Deals

CAM, Trilegal act on Adani’s latest $500mln QIP

by Nimitt Dixit |

Cyril Amarchand Mangaldas has represented Adani Enterprises, the Adani Group’s flagship entity, on its $500 million qualified institutional placement, with Trilegal advising the placement agents SBI Capital Markets, Jefferies India, and ICICI Securities.

Deals

CAM, Khaitan guide latest major India cement M&A

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising the Adani-held Ambuja Cement on its acquisition of 46.8 percent controlling stake in Orient Cement (OCL) for approximately $451 million. Khaitan & Co is representing OCL on the deal.